Compound heterozygosity of HLA-DRB3 * 01:01 and HLA-DRB4 * 01:01 as a potential predictor of fetal neonatal alloimmune thrombocytopenia

Transfusion

Volumn 53, Issue 2, 2013, Pages 344-352

  Loewenthal, Ron ^a,c,d   Rosenberg, Nurit ^a,c,d   Kalt, Rivka ^a,c,d   Dardik, Rima ^a,c,d   Landau, Meytal ^a,c,d   Yahalom, Vered ^a,c,d   Avishai, Ofelia ^a,c,d   Frenkel, Orit ^a,c,d   Gazit, Ephraim ^a,c,d   Steinberg, David M ^a,c,d   Lipitz, Shlomo ^a,c,d   Salomon, Ophira ^b  

^a Tissue Typing Laboratory   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d National Blood Services   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BETA3 INTEGRIN; HLA ANTIGEN CLASS 1; HLA DRB3 ANTIGEN; HLA DRB4 ANTIGEN; IMMUNOGLOBULIN G; INTEGRIN; THROMBOCYTE ANTIGEN;

ADULT; ALLELE; ANTIGEN SPECIFICITY; ARTICLE; BETA CHAIN; BLOOD GROUP TYPING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FAMILY; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HUMAN; LYMPHOCYTOTOXICITY; NEONATAL ALLOIMMUNE THROMBOCYTOPENIA; RISK ASSESSMENT; TREATMENT RESPONSE;

CASE-CONTROL STUDIES; FEMALE; FETAL DISEASES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HETEROZYGOTE; HLA-DRB1 CHAINS; HLA-DRB3 CHAINS; HUMANS; INFANT, NEWBORN; MODELS, MOLECULAR; PEDIGREE; PREGNANCY; PROGNOSIS; PROTEIN STRUCTURE, QUATERNARY; THROMBOCYTOPENIA, NEONATAL ALLOIMMUNE;

EID: 84873481527     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2012.03734.x     Document Type: Article

References (28)

1. Arnold DM, Smith JW, Kelton JG,. Diagnosis and management of neonatal alloimmune thrombocytopenia. Transfus Med Rev 2008; 22: 255-67.
2. Landau M, Rosenberg N,. Molecular insight into human platelet antigens: structural and evolutionary conservation analyses offer new perspective to immunogenic disorders. Transfusion 2011; 51: 558-69.
3. Bussel JB, Zabusky MR, Berkowitz RL, McFarland JG,. Fetal alloimmune thrombocytopenia. N Engl J Med 1997; 337: 22-6.
4. Newman PJ, Derbes RS, Aster RH,. The human platelet alloantigens, PlA1 and PlA2, are associated with a leucine33/proline33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing. J Clin Invest 1989; 83: 1778-81.
5. Denzin LK, Cresswell P,. HLA-DM induces CLIP dissociation from MHC class II alpha beta dimers and facilitates peptide loading. Cell 1995; 82: 155-65.
6. Parry CS, Gorski J, Stern LJ,. Crystallographic structure of the human leukocyte antigen DRA, DRB0101: models of a directional alloimmune response and autoimmunity. J Mol Biol 2007; 371: 435-46.
7. Ahlen MT, Husebekk A, Killie MK, Skogen B, Stuge TB,. T-cell responses associated with neonatal alloimmune thrombocytopenia: isolation of HPA1a specific, HLA-DRB30101 resstricted T cells. Blood 2009; 113: 3838-44.
8. Rayment R, Kooij TW, Zhang W, Siebold C, Murphy MF, Allen D, Willcox N, Roberts DJ,. Evidence for the specificity for platelet HPA-1a alloepitope and the presenting HLADR52a of diverse antigen-specific helper T cell clones from alloimmunized mothers. J Immunol 2009; 183: 677-86.
9. Sharon R, Amar A,. Maternal anti-HLA antibodies and neonatal thrombocytopenia. Lancet 1981; 8233: 1313.
10. Bussel JB, Berkowitz RL, Hung C, Kolb EA, Wissert M, Primiani A, Tsaur FW, Macfarland JG,. Intracranial hemorrhage in alloimmune thrombocytopenia: stratified management to prevent recurrence in the subsequent affected fetus. Am J Obstet Gynecol 2010; 203: 135.e1-14.
11. Mechoulan A, Kaplan C, Muller JY, Branger B, Philippe HJ, Oury JF, Ville Y, Winer N,. Fetal alloimmune thrombocytopenia: is less invasive antenatal management safe? J Matern Fetal Neonatal Med 2011; 24: 564-7.
12. Bertrand G, Drame M, Martageix C, Kaplan C,. Prediction of the fetal status in non-invasive management of alloimmune thrombocytopenia. Blood 2011; 117: 3209-13.
13. Vinograd CA, Bussel JB,. Antenatal treatment of fetal alloimmune thrombocytopenia: a current perspective. Haematologica 2010; 95: 1807-11.
14. Giers G, Wenzel F, Stockschläder M, Riethmacher R, Lorenz H,. Fetal alloimmune thrombocytopenia and maternal intravenous immunoglobulin infusion. Haematologica 2010; 95: 1921-6.
15. Arnold K, Bordoli L, Kopp J, Schwede T,. The SWISS-MODEL Workspace: a web-based environment for protein structure homology modelling. Bioinformatics 2006; 22: 195-201.
16. Saline M, Rödström KE, Fischer G, Orekhov VY, Karlsson BG, Lindkvist-Petersson K,. The structure of superantigen complexed with TCR and MHC reveals novel insights into superantigenic T cell activation. Nat Commun 2010; 1: 119.
17. Williamson LM, Hackett G, Rennie J, Palmer CR, Maciver C, Hadfield R, Hughes D, Jobson S, Ouwehand WH,. The natural history of fetomaternal alloimmunization to the platelet-specific antigen HPA-1a (PlA1, Zwa) as determined by antenatal screening. Blood 1998; 92: 2280-7.
18. L'Abbé D, Tremblay L, Filion M, Busque L, Goldman M, Décary F, Chartrand P,. Alloimmunization to platelet antigen HPA-1a (PIA1) is strongly associated with both HLA-DRB30101 and HLA-DQB10201. Hum Immunol 1992; 34: 107-14.
19. Décary F, L'Abbé D, Tremblay L, Chartrand P,. The immune response to the HPA-1a antigen: association with HLADRw52a. Transfus Med 1991; 1: 55-62.
20. Valentin N, Vergracht A, Bignon JD, Cheneau ML, Blanchard D, Kaplan C, Reznikoff-Etievant MF, Muller JY,. HLA-DRw52a is involved in alloimmunization against PL-A1 antigen. Hum Immunol 1990; 27: 73-7.
21. Anani Sarab G, Moss M, Barker RN, Urbaniak SJ,. Naturally processed peptides spanning the HPA-1 polymorphism are efficiently generated and displayed from platelet glycoprotein by HLA-DRB30101-positive antigen- presenting cells. Blood 2009; 114: 1954-7.
22. Kjeldsen-Kragh J, Killie MK, Tomter G, Golebiowska E, Randen I, Hauge R, Aune B, Øian P, Dahl LB, Pirhonen J, Lindeman R, Husby H, Haugen G, Grønn M, Skogen B, Husebekk A,. A screening and intervention program aimed to reduce mortality and serious morbidity associated with severe neonatal alloimmune thrombocytopenia. Blood 2007; 110: 833-9.
23. Killie MK, Husebekk A, Kjeldsen-Kragh J, Skogen B,. A prospective study of maternal anti-HPA 1a antibody level as a potential predictor of alloimmune thrombocytopenia in the newborn. Haematologica 2008; 93: 870-7.
24. Steck AK, Rewers MJ,. Genetics of type I diabetes. Clin Chem 2011; 57: 176-85.
25. Westman P, Hashemi-Tavoularis S, Blanchette V, Kekomäki S, Laes M, Porcelijn L, Kekomäki R,. Maternal DRB11501, DQA10102, DQB10602 haplotype in fetomaternal alloimmunization against human platelet alloantigen HPA-6b (GPIIIa-Gln489). Tissue Antigens 1997; 50: 113-8.
26. Sachs UJ, Socher I, Braeunlich CG, Kroll H, Bein G, Santoso S,. A variable number of tandem repeats polymorphism influences the transcriptional activity of the neonatal Fc receptor alpha-chain promoter. Immunology 2006; 119: 83-9.
27. Firan M, Bawdon R, Radu C, Ober RJ, Eaken D, Antohe F, Ghetie V, Ward ES,. The MHC class-I related receptor, FcRn, plays an essential role in the maternofetal transfer of gamma-globulin in humans. Int Immunol 2001; 13: 993-1002.
28. Chen P, Li C, Lang S, Zhu G, Reheman A, Spring CM, Freedman J, Ni H,. Animal model of fetal and neonatal immune thrombocytopenia: role of neonatal Fc receptor in the pathogenesis and therapy. Blood 2010; 116: 3660-8.